United States - English - NLM (National Library of Medicine)

biocsl pty ltd. - influenza a virus a/california/7/2009 x-181 (h1n1) antigen (propiolactone inactivated) (unii: bh0r06yxfz) (influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:mhg4xw7big), influenza a virus a/south australia/55/2014 ivr-175 (h3n2) antigen (propiolactone inactivated) (unii: 5087bpo79o) (influenza a virus a/south australia/55/2014 ivr-175 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:9a68j3t9te), influenza b virus b/phuket/3073/2013 ant - influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - afluria® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b present in the vaccine. afluria is approved for use in persons 5 years of age and older. afluria is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy category b: a reproductive and developmental toxicity study has been performed in female rats at a dose approximately 265 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to afluria. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, afluria should be given to a pregnant woman only if clearly needed. in the reproductive and developmental toxicity study, the effect

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - tramadol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - tramadol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - tramadol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - tapentadol hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - human papillomavirus (hpv) 11 l1 protein 80 µg/ml;  ; human papillomavirus (hpv) 16 l1 protein 80 µg/ml;  ; human papillomavirus (hpv) 18 l1 protein 40 µg/ml;  ; human papillomavirus (hpv) 6 l1 protein 40 µg/ml;   - solution for injection - active: human papillomavirus (hpv) 11 l1 protein 80 µg/ml   human papillomavirus (hpv) 16 l1 protein 80 µg/ml   human papillomavirus (hpv) 18 l1 protein 40 µg/ml   human papillomavirus (hpv) 6 l1 protein 40 µg/ml   excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax histidine polysorbate 80 sodium chloride water for injection - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16 and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infections caused by hpv types 6, 11, 16 and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 20 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 40 microgram; hpv type 18 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: aluminium; histidine; polysorbate 80; borax; water for injections; sodium chloride - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - hepatitis b surface antigen recombinant -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - pneumococcal purified capsular polysaccharides -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - hepatitis a virus antigen -